123 related articles for article (PubMed ID: 10066792)
1. Mutation of a conserved serine residue in a quinolone-resistant type II topoisomerase alters the enzyme-DNA and drug interactions.
Strumberg D; Nitiss JL; Rose A; Nicklaus MC; Pommier Y
J Biol Chem; 1999 Mar; 274(11):7292-301. PubMed ID: 10066792
[TBL] [Abstract][Full Text] [Related]
2. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
Hsiung Y; Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1995 Sep; 270(35):20359-64. PubMed ID: 7657608
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions.
Strumberg D; Nitiss JL; Dong J; Kohn KW; Pommier Y
J Biol Chem; 1999 Oct; 274(40):28246-55. PubMed ID: 10497180
[TBL] [Abstract][Full Text] [Related]
4. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
5. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
[TBL] [Abstract][Full Text] [Related]
6. The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
Jannatipour M; Liu YX; Nitiss JL
J Biol Chem; 1993 Sep; 268(25):18586-92. PubMed ID: 8395511
[TBL] [Abstract][Full Text] [Related]
7. Atp-bound topoisomerase ii as a target for antitumor drugs.
Wang H; Mao Y; Zhou N; Hu T; Hsieh TS; Liu LF
J Biol Chem; 2001 May; 276(19):15990-5. PubMed ID: 11278845
[TBL] [Abstract][Full Text] [Related]
8. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
9. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
10. Importance of the fourth alpha-helix within the CAP homology domain of type II topoisomerase for DNA cleavage site recognition and quinolone action.
Strumberg D; Nitiss JL; Dong J; Walker J; Nicklaus MC; Kohn KW; Heddle JG; Maxwell A; Seeber S; Pommier Y
Antimicrob Agents Chemother; 2002 Sep; 46(9):2735-46. PubMed ID: 12183223
[TBL] [Abstract][Full Text] [Related]
11. A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.
Elsea SH; Hsiung Y; Nitiss JL; Osheroff N
J Biol Chem; 1995 Jan; 270(4):1913-20. PubMed ID: 7829529
[TBL] [Abstract][Full Text] [Related]
12. Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
Leontiou C; Lakey JH; Austin CA
Mol Pharmacol; 2004 Sep; 66(3):430-9. PubMed ID: 15322234
[TBL] [Abstract][Full Text] [Related]
13. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.
Vassetzky YS; Alghisi GC; Roberts E; Gasser SM
Br J Cancer; 1996 May; 73(10):1201-9. PubMed ID: 8630279
[TBL] [Abstract][Full Text] [Related]
14. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Moynihan M; Sutcliffe JA; Osheroff N
J Biol Chem; 1991 Aug; 266(22):14585-92. PubMed ID: 1650363
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced conformational population shifts in topoisomerase-DNA ternary complexes.
Huang NL; Lin JH
Molecules; 2014 Jun; 19(6):7415-28. PubMed ID: 24905608
[TBL] [Abstract][Full Text] [Related]
16. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
17. DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives.
Huff AC; Robinson RG; Evans AC; Selander KN; Wentland MP; Rake JB; Coughlin SA
Anticancer Drug Des; 1995 Apr; 10(3):251-76. PubMed ID: 7748459
[TBL] [Abstract][Full Text] [Related]
18. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
Wasserman RA; Wang JC
Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
[TBL] [Abstract][Full Text] [Related]
19. Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Fisher LM
Br J Cancer; 1993 Mar; 67(3):456-63. PubMed ID: 8382508
[TBL] [Abstract][Full Text] [Related]
20. Molecular cloning and expression of the Candida albicans TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast.
Keller BA; Patel S; Fisher LM
Biochem J; 1997 May; 324 ( Pt 1)(Pt 1):329-39. PubMed ID: 9164874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]